NCT04251676

Brief Summary

We wish to study radiation therapy in uterine cancer, focusing on dosimetry analysis, clinical implication, and survival analysis.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
200

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jan 2010

Longer than P75 for all trials

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2010

Completed
9.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 30, 2019

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

January 30, 2020

Completed
6 days until next milestone

First Posted

Study publicly available on registry

February 5, 2020

Completed
1.8 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2021

Completed
Last Updated

February 11, 2021

Status Verified

January 1, 2021

Enrollment Period

9.8 years

First QC Date

January 30, 2020

Last Update Submit

February 10, 2021

Conditions

Endometrial Cancer

Outcome Measures

Primary Outcomes (1)

  • Progression free survival

    Progression free survival: The time from inclusion to documented disease progression according to RECIST v1.1 or death from any cause.

    5 years

Interventions

Observational studyOTHER

Observational study

Eligibility Criteria

Age20 Years - 100 Years
Sexfemale(Gender-based eligibility)
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Women with uterine cancer (stage I - IV) treated in National Taiwan University Hospital, from January 2010 to September 2019.

You may qualify if:

  • Women with uterine cancer (stage I - IV) treated in National Taiwan University Hospital, from January 2010 to September 2019.

You may not qualify if:

  • Women with uterine cancer (stage I - IV) NOT treated in National Taiwan University Hospital, from January 2010 to September 2019.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (1)

  • Chen JL, Huang YS, Huang CY, Hsu CY, Lan KH, Cheng WF, Kuo SH. Impact of adjuvant radiotherapy on the survival of women with optimally resected stage III endometrial cancer in the era of modern radiotherapy: a retrospective study. Radiat Oncol. 2020 Apr 6;15(1):72. doi: 10.1186/s13014-020-01523-5.

    PMID: 32252781DERIVED

MeSH Terms

Conditions

Endometrial Neoplasms

Interventions

Observation

Condition Hierarchy (Ancestors)

Uterine NeoplasmsGenital Neoplasms, FemaleUrogenital NeoplasmsNeoplasms by SiteNeoplasmsUterine DiseasesGenital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesGenital Diseases

Intervention Hierarchy (Ancestors)

MethodsInvestigative Techniques

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 30, 2020

First Posted

February 5, 2020

Study Start

January 1, 2010

Primary Completion

September 30, 2019

Study Completion

December 1, 2021

Last Updated

February 11, 2021

Record last verified: 2021-01

Data Sharing

IPD Sharing
Will not share